Back to search results

Observational Study of GEP-NET Treatment Patterns and Outcomes

This study is looking at how gastroenteropancreatic neuroendocrine tumor (GEP-NET) is currently treated in the United States and what the results of those treatments are. It's an observational study, meaning researchers will look at existing medical records rather than giving new treatments. They are interested in understanding the different types of treatments patients receive, how many different treatments they try, and the specific medicines used. The study is open to adults aged 18 to 110 years old who have a GEP-NET diagnosis and have started their first systemic (body-wide) therapy. The study is currently unclear on its recruitment status.

Study design
This is an observational study that aims to include 4023 participants. It will analyze existing medical and prescription claims data.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at treatment patterns and outcomes for up to approximately 8 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07635316

A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Recruiting
Not specifiedAges 18+Observational
Novartis Pharmaceuticals
~4,023 participants
Updated 2026-07-06 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Lines of Therapy (LOTs)
Measured over Up to approximately 8 years
+5 more outcomes measured

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Explore related trials

Digestive System Neuroendocrine Tumor

NCT07635316

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Novartis

    East Hanover, New Jerseyno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Novartis Pharmaceuticals · STUDY_DIRECTOR · Novartis Pharmaceuticals

Who to contact

Novartis Pharmaceuticals
[email protected]
+41613241111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Number of Lines of Therapy (LOTs)Up to approximately 8 years
  • Number and Percentage of Patients by Treatment Regimen per LOTUp to approximately 8 years
  • Number and Percentage of Patients by Type of Therapy in Each LOTUp to approximately 8 years
  • Number and Percentage of Patients who Discontinue all Medications Within the 1L Treatment RegimenUp to approximately 8 years
  • Number of Cycles of Medications Within the Treatment Regimen Before DiscontinuationUp to approximately 8 years
  • Time to 1L Treatment DiscontinuationUp to approximately 8 years